Authors
Sebastiaan Dhont, Sara Moura Ferreira, Jan Stassen, Lieven Herbots, Sarah Hoedemakers, Youri Bekhuis, Ruta Jasaityte, Sarah Stroobants, Thibault Petit, Elise Bakelants, Maarten Falter, Guido Claessen, Petra Nijst, Pieter M Vandervoort, Philippe B Bertrand, Jan Verwerft
Published in
European heart journal. Valvular and structural heart disease. Volume 2. Issue 3. Pages xwag050. Epub Jun 19, 2026.
Abstract
Exercise-induced pulmonary hypertension (PH), defined by a mean pulmonary arterial pressure over cardiac output (mPAP/CO) slope >3 mmHg/L/min has important diagnostic and prognostic implications.
The aim of this study is to investigate the value of the mPAP/CO slope in patients with at least moderate primary MR with preserved ejection fraction and no or discordant symptoms.
A total of 184 consecutive patients were evaluated with exercise echocardiography and cardiopulmonary testing. Clinical outcome was defined as the composite of mitral valve intervention, new-onset atrial fibrillation, cardiovascular hospitalization, and all-cause mortality.
Mean age was 63 years, 59% male, and mean LVEF 67 ± 6%. The mPAP/CO slope correlated with peak VO2 (r = -0.37, P < .001), while peak sPAP did not (r = -0.05, P = .517). Thirty-nine per cent (n = 73) had peak exercise sPAP ≥60 mmHg, and 32% (n = 58) had mPAP/CO slope >3 mmHg/L/min. Event-free survival was 71% at 1 year and 59% at 2 years, with more clinical events in patients with mPAP/CO slope >3 mmHg/L/min (HR of 4.1 (95% CI 2.6-6.5). In 61 patients, mPAP/CO slope and peak sPAP were discordant. Patients with slope >3 mmHg/L/mmHg and sPAP <60 mmHg (n = 23) had worse outcome versus peak sPAP ≥60 mmHg and normal slope (n = 38, log rank P = .037). The mPAP/CO slope improved predictive models for outcome, incremental to resting and exercise sPAP, and peak VO2.
Exercise PH defined by the mPAP/CO slope >3 mmHg/L/min is associated with decreased exercise capacity and higher risk of adverse events in significant primary MR and no or discordant symptoms. The slope provides a greater prognostic value than single sPAP measures and peak VO2.
PMID:
43053868
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0